TENAX THERAPEUTICS, INC. Marketable Securities, Unrealized Gain (Loss)
TENAX THERAPEUTICS, INC. (TENX) reported Marketable Securities, Unrealized Gain (Loss) of $70 for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-03-31
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2021-09-30 was $276.00.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2021-06-30 was $128.00.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2021-03-31 was -$332.00.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2019-09-30 was -$960.00, a 114.74% decline year-over-year.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was $70.00.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2018 was $16.71K, a 561.74% increase from fiscal 2017.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2017 was $2.52K, a 97.72% decline from fiscal 2016.
- TENAX THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2016 was $110.72K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 8 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $70.00 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $276.00 10-Q · filed 2022-11-10 | $404.00 derived: sum of 2 quarters · filed 2022-11-10 | $72.00 derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $128.00 10-Q · filed 2022-11-10 | -$204.00 derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | -$332.00 10-Q · filed 2022-11-10 | ||||
| 2019-09-30 | -$960.00 10-Q · filed 2019-11-14 | -$486.00 derived: sum of 2 quarters · filed 2019-11-14 | $803.00 derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2019-06-30 | $474.00 10-Q · filed 2019-11-14 | $1.76K derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2019-03-31 | $1.29K 10-Q · filed 2019-11-14 | ||||
| 2018-12-31 | $16.71K 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | $6.51K 10-Q · filed 2019-11-14 | $17.07K derived: sum of 2 quarters · filed 2019-11-14 | $6.21K derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2018-06-30 | $10.55K 10-Q · filed 2019-11-14 | -$302.00 derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2018-03-31 | -$10.86K 10-Q · filed 2019-11-14 | ||||
| 2017-12-31 | $2.52K 10-K · filed 2019-04-01 | ||||
| 2016-12-31 | $110.72K 10-K · filed 2018-04-02 | ||||
| 2015-12-31 | -$156.16K 10-K · filed 2017-03-16 | ||||
| 2015-04-30 | $26.72K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |